Heterogeneity among Mycobacterium avium complex species isolated from pulmonary infection in Taiwan
- PMID: 40621928
- PMCID: PMC12323620
- DOI: 10.1128/spectrum.00309-25
Heterogeneity among Mycobacterium avium complex species isolated from pulmonary infection in Taiwan
Abstract
Mycobacterium avium complex (MAC) is an emerging pathogen causing nontuberculous pulmonary infections globally. However, clinical treatment guidelines regard MAC as a single entity, recommending a universal anti-mycobacterial combination therapy. Our study aimed to distinguish species among MAC and investigate the antimicrobial susceptibility for the selection of optimal antimicrobial agents in Taiwan. Two hundred ninety-four consecutive sputum samples confirmed as MAC by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were collected from 1 November 2015 to 31 August 2020 at Linkou Chang Gung Memorial Hospital in Taiwan. These isolates were identified through 16S rRNA gene, 23S rRNA gene, heat-shock protein 65 gene (hsp65), internal transcribed spacer, and beta subunit of RNA polymerase (rpoB) gene sequencing and phylogenetic analyses. Antimicrobial susceptibility testing (AST) was performed with 13 antimicrobial agents. The predominant pathogen identified was Mycobacterium intracellulare clade A (122/294, 41.5%), followed by M. intracellulare subsp. chimaera (87/294, 29.6%), M. intracellulare subsp. intracellulare (39/294, 13.3%), M. avium (35/294, 11.9%), and four other species (11/294, 3.7%). AST showed that clarithromycin and amikacin had high susceptibility rates against M. intracellulare clade A, M. intracellulare subsp. chimaera, M. intracellulare subsp. intracellulare, and M. avium, while linezolid and moxifloxacin exhibited higher resistance. The comparison of minimum inhibitory concentrations among species within the same antimicrobial agent showed variability in susceptibility. A diverse clonality of M. intracellulare might exist in MAC pulmonary infections in Taiwan. Among MAC species, M. avium exhibited multidrug resistance. Although international guidelines recommend macrolide, ethambutol, and rifampin for treating MAC pulmonary disease, our study highlights the importance of considering species identification and regional AST results when selecting anti-mycobacterial agents.IMPORTANCEThere are more than 10 (sub)species within the Mycobacterium avium complex. According to modern biotechnology, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, it is still difficult to differentiate the complex into specific species precisely. We utilize concatenated multi-gene sequencing to classify this complex at the (sub)species level. Indeed, we encountered poorer treatment outcomes when facing Mycobacterium avium pulmonary infections compared to other species causing pulmonary infections. Individualized anti-mycobacterial therapy should focus on each species responsible for pulmonary disease.
Keywords: combination therapy; concatenated gene sequences; genetic diversity; multidrug resistance; phylogenetic analysis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.Chest. 2024 May;165(5):1058-1069. doi: 10.1016/j.chest.2023.12.006. Epub 2023 Dec 10. Chest. 2024. PMID: 38086472 Free PMC article.
-
Clinical features of patients with bacteraemia caused by Mycobacterium avium complex species and antimicrobial susceptibility of the isolates at a medical centre in Taiwan, 2008-2014.Int J Antimicrob Agents. 2017 Jul;50(1):35-40. doi: 10.1016/j.ijantimicag.2017.02.016. Epub 2017 May 3. Int J Antimicrob Agents. 2017. PMID: 28478210
-
Whole-genome phylogenetic analysis of Mycobacterium avium complex from clinical respiratory samples.Microbiol Spectr. 2025 Feb 4;13(2):e0160024. doi: 10.1128/spectrum.01600-24. Epub 2025 Jan 10. Microbiol Spectr. 2025. PMID: 39792017 Free PMC article.
-
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039. Cochrane Database Syst Rev. 2025. PMID: 40145528
-
Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. J Antimicrob Chemother. 2017. PMID: 28922813
References
-
- Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. 1998. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 27:1278–1285. doi: 10.1086/514999 - DOI - PubMed
-
- Ye JJ, Wu TS, Chiang PC, Lee MH. 2007. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease. J Microbiol Immunol Infect 40:342–348. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials